Shattuck Labs, Inc. (STTK)
After hours:
- GuruFocus.com
Shattuck Labs Inc (STTK) Reports First Quarter 2024 Financial Results
Performance Showcases Strategic Advancements Amid Financial Challenges
- Zacks
Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue Estimates
Shattuck Labs (STTK) delivered earnings and revenue surprises of 21.28% and 457.50%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of 2024; updated combination data expected at the European Society of Hematology (EHA) 2024 Annual Meeting in June – - Randomized, controlled Phase 1B dose-expansion cohort in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) patients expected to initiate enrollment in the second quarter of 2024 – - Presented preclinical data at the 2024 A
